No Data
No Data
Tracking of Hong Kong stock concepts | The Medical Insurance Bureau has announced the new medical insurance catalog. Institutions believe that the golden opportunity to increase the allocation of the pharmaceutical sector has already opened (including con
The National Medical Insurance Bureau has conducted preliminary reviews on 440 pharmaceuticals for this year's medical insurance catalog, which is an increase from last year.
CICC: The pharmaceutical sector has entered a value investment range, focusing on the domestic innovative drug industry chain and going overseas.
China International Capital Corporation released a research report stating that after three years of systematic adjustment, the pharmaceutical sector has entered the range of value investment.
Zhitong Hong Kong Stock Early Access | Overnight, the three major stock indexes of the US stock market collectively fell sharply. Five departments: strengthen financial support for the comprehensive revitalization of rural areas special action.
Recently, the People's Bank of China, the General Administration of Financial Regulation, the China Securities Regulatory Commission, the Ministry of Finance, and the Ministry of Agriculture and Rural Affairs jointly issued a notice on carrying out a special action to strengthen financial support for the comprehensive revitalization of rural areas by learning from the experience of the 'Millions of Project'.
Express News | Antennova Announces Cd73 Small Molecule Inhibitor Accepted for Mini Oral Presentation at Esmo Congress 2024
Deqi Pharmaceutical-B (06996.HK): The new drug applications for two indications of Xyvio have been approved by the National Pharmaceutical Regulatory Agency of Malaysia.
Deqi Pharmaceuticals-B (06996.HK) announced that the Malaysian National Pharmaceutical Regulatory Agency has approved the new drug application (NDA) for Xyvio (selinexor tablets) for two indications: (1) when used in combination with bortezomib and dexamethasone, it is used to treat adult patients with relapsed/refractory multiple myeloma (MM) who have received at least one prior therapy; and (2) when used in combination with dexamethasone, it is used to treat adult patients with relapsed/refractory MM who have received at least four prior therapies, including at least two proteasome inhibitors, two immunomodulatory agents, and one anti-CD38 monoclonal antibody, and whose disease has progressed on the last therapy.
Express News | Antengene Corp - Approval of Nda by Malaysian National Pharmaceutical Regulatory Agency for Xpovio for Two Indications
No Data